IJGC conversations

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Stephanie Gill to discuss ICG Angiography for Bowel Anastomosis Evaluation.   Stephanie J. Gill, MD, FRCSC, MSc, MScHSE, is a second-year Gynecologic Oncology Fellow at the University of Toronto in Toronto, Canada, with clinical appointments at Princess Margaret Cancer Centre and the Odette Cancer Centre. She holds two Master’s degrees in Medical Sciences—focused on biostatistics and epidemiology—and Health Sciences Education, with a particular interest in robotic surgery training and competency-based assessment. Her research interests include surgical innovation and enhanced recovery after surgery, outcomes in rare gynecologic malignancies such as vulvar cancer and gestational trophoblastic neoplasia, and quality improvement in gynecologic oncology.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Mariana Scaranti to discuss ESMO 2025 Highlights: Top Studies In Gynecologic Oncology.   Mariana Scaranti, MD, is a Brazilian medical oncologist dedicated to gynecologic oncology. She practices at Hospital 9 de Julho in São Paulo and is the National Lead for Gynecologic Oncology at Rede Américas, Brazil. She serves as Research Director of Grupo EVA, the Brazilian Gynecologic Oncology Group, and is a member of the Gynecologic Tumors Committee of the Brazilian Society of Clinical Oncology (SBOC). She previously trained as a fellow at The Royal Marsden NHS Foundation Trust in London

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Nicole Concin to discuss ESGO-ESTRO-ESP 2025 Endometrial Cancer Guidelines.   Professor Concin serves as the Chair of the Department of Gynaecology and Gynaecological Oncology and as Director of the Department of Obstetrics and Gynaecology at the Medical University of Vienna. She is President of the Austrian Network of Gynaecologic Oncology (AGO Austria), Executive Committee member of the European Society of Gynaecological Oncology (ESGO), immediate Past-President of the ESGO, Board of Directors member of GCIG Gynaecologic Cancer InterGroup (GCIG), education faculty member for gynaecological cancer of the European Society of Medical Oncology (ESMO) and Board member of the International Federation of Gynaecology and Obstetrics (FIGO) Committee on Women’s Cancer. Professor Concin’s clinical, research and teaching focus is gynaecological oncology. She has led multiple translational and clinical research projects worldwide and provided her expertise in >100 international clinical trials in gynaecological oncology, several of which she served as Principal or Global Coordinating Investigator. She has authored >150 research articles inhighly ranked peer-reviewed Journals. Her most cited article is the European multidisciplinary guidelines for the management of patients with endometrial carcinoma (Concin N. et al, IJGC Dec 2020; >1300 citations). In recognition of Professor Concin’s ability and achievements, she has received multiple grants and awards including the award of the Austrian Society for Cancer Aid, i.e. the Univ. Prof. DDr. Karl Fellinger Award. Her recent article in Lancet Oncology, “ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: Update 2025,” presents the latest revision of the guidelines, building upon the previous version published in 2021.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Cristina Taliento and Giuseppe Vizzielli to discuss ctDNA & diagnosis of ovarian cancer.   Cristina Taliento is a gynecologist and PhD candidate in a joint PhD program at the University Hospital of Ferrara, Italy, and KU Leuven, Belgium, associated with the International Ovarian Tumour Analysis (IOTA) Group. She completed a Research Fellowship at the European Institute of Oncology in Milan. She recently started her Fellowship Training in Gynecologic Oncology at the University Hospital of Heidelberg, Germany. Her PhD research focuses on clinical and translational studies in the diagnosis and management of adnexal tumors, with a particular interest in circulating tumor DNA in ovarian cancer.   Giuseppe Vizzielli is an associate professor of gynecology and obstetrics at the Department of Medicine, University of Udine, and Chief of the Gynecologic Oncology Unit at University Hospital of Udine, Italy. He completed his Ph.D. studies in molecular pathology in gynaecological oncology at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma. He is a member of the European Society of Gynaecological Oncology (ESGO) and a member of the Italian Society of Gynaecological Endoscopy (SEGI), affiliated with the ESGE. He was the principal investigator of the national research project,  Longitudinal genomic and transcriptomic analysis on ovarian cancer organoids. He serves as an official reviewer of many indexed international journals as well as Lancet Oncology, the International Journal of Gynecological Cancer, the European Journal of Surgical Oncology, World Journal of Surgical Oncology, European Journal of Obstetrics and Gynecology and Reproductive Biology, Archives of Gynecology and Obstetrics, and BMC Cancer, and he is an associate editor of BMC Cancer, Cancers and the World Journal of Surgical Oncology. His recent publication in IJGC focuses on Circulating tumor DNA in the diagnosis of ovarian cancer.      

In this episode of the IJGC conversations 2025 December Editor's Choice, Editorial Fellow Itziar Villagrá, Joannie Neveu, and Mathilde Del discusses the contents of the 2025 December issue of IJGC.   

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Bradley Monk to discuss ctDNA: Results from CALLA Trial.   Bradley Monk, MD, FACOG, FACS is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute and medical director of the Late-Stage Clinical Research Program. He provides care to patients at the FCS West Palm Beach location. Dr. Monk has extensive leadership experience in practice-changing clinical research and the development of clinical research programs in community oncology settings. His research special interests are primarily focused on the prevention and treatment of gynecologic cancers. As a principal investigator, Dr. Monk has been involved in numerous groundbreaking studies throughout his career. Dr. Monk is a co-founder of the GOG-Partners (GOG-P) Foundation® (GOG-F), a nonprofit organization committed to advancing clinical and scientific research in the field of gynecologic malignancies. The organization was instrumental in establishing a national gynecologic clinical trials network. He has presented his findings at hundreds of national and international forums and authored more than 400 peer-reviewed articles and more than 35 book chapters focused on the prevention and treatment of gynecologic malignancies and patient reported outcomes. Dr. Monk is a past recipient of the esteemed Ernst Wertheim Award for his research in cervical cancer. Prior to joining FCS in 2024, Dr. Monk served as director and principal investigator for HonorHealth at the Virginia G. Piper Cancer Center in Scottsdale, Arizona, where he also served as the site research leader for Sarah Cannon Research Institute. Among his numerous academic appointments, he most recently served as a professor on the Clinical Scholar Track at the University of Arizona College of Medicine.

In this IJGC podcast, Dr. Pedro Ramirez discusses RAMP 201 Results: Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer with Susana N Banerjee and Rachel N. Grisham. Prof Susana Banerjee MBBS MA PhD FRCP is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust, London. She is also Professor in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers. Prof Banerjee is President of the Royal Society of Medicine Oncology Section. Prof Banerjee graduated with a 1st class in Physiology from St John’s College, University of Cambridge. She was president of the Cambridge Medical Society in 1996-1997. She completed her medical training in 2000 at The Royal Free/University College London Medical School where she was a University of London Gold Medal finalist. Dr Banerjee gained a PhD from The Institute of Cancer Research in 2009, University of London and was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research. Other prizes include the Association of Cancer Physicians McElwain Prize, the Sir Antony Driver Prize and the Pfizer British Oncology Association Young Investigator Award (highly commended). She received The Fellow of ESMO (FESMO) Award in 2023. Prof Banerjee has served in international specialist groups including the European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, ESGO (European Society of Gynaecological Oncology) Congress Faculty and International Gynecologic Cancer Society Scientific Program Committee. Prof Susana Banerjee was elected to serve on the European Society of Medical Oncology (ESMO) Executive Board as Director of Membership (2020-2022). She was Track Chair for Gynaecological Cancers for the ESMO Congress 2018, Scientific Co-Chair for ESMO Asia 2018 and Co-Chair of the ESMO Gynaecological Cancers Congress 2021-2024. She is currently co-chair of the Gynecological Cancer InterGroup (GCIG) Rare Cancers Committee. She is a Theme Lead (Cancer Treatment Effects) for the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research. Prof Banerjee is an author of over 200 peer-reviewed publications including in the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Her research interests include individualisation of patient treatment, targeted therapies (including PARP inhibitors) and rare gynaecological cancers. Prof Banerjee has Global and UK Chief Investigator roles of over 30 national and international clinical trials. She led the ENGOTov60/GOG3052/RAMP201 trial globally which resulted in FDA accelerated approval for avutometinib and defactanib - the first approved therapy specifically for low grade serous ovarian cancer.   Dr. Rachel N. Grisham is a medical oncologist and internationally recognized expert in gynecologic cancers, with a particular focus on low-grade serous ovarian carcinoma (LGSOC) and rare ovarian malignancies. She has played a leading role in advancing systemic therapy for ovarian cancer through clinical trials, translational research, and national guideline development. Dr. Grisham has been at the forefront of evaluating novel targeted therapies for LGSOC, including MEK inhibitors, avutometinib, and defactinib, as well as hormone-directed strategies and combinations with novel agents. She has served as principal or co-investigator on multiple pivotal trials, including ENGOT-OV60/GOG-3052/RAMP 201 and RAMP 301, which are shaping the future treatment landscape for recurrent LGSOC. Her work extends to biomarker-driven approaches, exploring MAPK pathway alterations, homologous recombination deficiency, and folate receptor alpha expression, with the goal of developing precision oncology strategies in ovarian cancer. In addition to clinical trials, Dr. Grisham has published extensively on the molecular landscape and clinicopathologic features of ovarian tumors, treatment paradigms for granulosa cell tumors and clear cell carcinoma, and the management of rare gynecologic neoplasms such as mesonephric-like adenocarcinomas. She is a co-author of the NCCN Guidelines for Ovarian, Fallopian Tube, and Primary Peritoneal Cancers, reflecting her leadership in shaping standards of care. Her scholarly contributions include over a decade of influential publications in Journal of Clinical Oncology, Clinical Cancer Research, Gynecologic Oncology, International Journal of Gynecological Cancer, and Cancer. She has also authored consensus statements and state-of-the-science reviews that provide critical guidance for clinicians worldwide. Through her clinical research, teaching, and collaborative international work, Dr. Grisham has made significant contributions to improving outcomes for women with gynecologic cancers, particularly those with low-grade serous ovarian cancer, a historically under-researched disease.

In this IJGC podcast, Dr. Pedro Ramirez discusses SENTIX Trial with David Cibula. Dr. David Cibula graduated from the First Faculty of Medicine at Charles University in Prague in 1992. Since 2003, he has served as the Chair of the Gynecological Oncology Center at the University Hospital in Prague, and in 2022, he became the head of the Department of Gynecology, Obstetrics, and Neonatology. He is a former President of the European Society of Gynecologic Oncology and previously led the International Group for Guidelines and Quality Indicators in Cervical Cancer. He is the founder and chair of the Central and Eastern European Group for Clinical Trials in Gynecologic Oncology, a member of ENGOT. Dr. Cibula has also established two charitable organizations supporting patients with gynecologic cancers and promoting research in the field. He is the author or co-author of hundreds of scientific publications. His recent article in Nature Cancer presents the final results of the SENTIX study on sentinel lymph node biopsy in early-stage cervical cancer.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Frédéric Amant to discuss ESGO/INCIP 2025 Guidelines for Cancer in Pregnancy.   Frédéric Amant (MD, PhD) received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998 and his subspecialty training in gynecologic oncology in 2000. He defended his thesis on uterine sarcomas in 2002 at the KU Leuven. He is specialist at the UZ Leuven in Belgium. He is professor at the KU Leuven in Belgium and at the University of Amsterdam in the Netherlands, and honorary professor at the university of Pretoria, South Africa. Since 2024 he is council member of the European Society of Gynecologic Oncology. Frédéric Amant heads the Gynecologic Oncology research section at the University of Leuven, Belgium and at the Netherlands Cancer Institute. In 2005 he founded the “International Network on Cancer, Infertility and Pregnancy” (INCIP)(www.cancerinpregnancy.org), and chairs this network up till now. Since 2014, INCIP also registers young women who aim to preserve their fertility. In 2021 he launched the Advisory Board Cancer Infertility Pregnancy (ABCIP) under the umbrella of INCIP. In addition, Frédéric Amant founded Trace, the tumor xenograft platform at the KU Leuven and the Fund for Innovative Research at the KU Leuven. He co-founded ENITEC, the European Network on Individualized Treatment of Endometrial Cancer. Since 2024 he is member of the research council at the KU Leuven.

In this IJGC podcast, Dr. Pedro Ramirez discusses SUROVA Study: Surgery vs Neoadjuvant Therapy in Ovarian Cancer with Luis Chiva.   Prof. Luis M. Chiva, MD, PhD, is Chair of Obstetrics and Gynecology and Professor of Gynecology and Medical Ethics at the University of Navarra in Pamplona, Spain. An internationally recognized leader in gynecologic oncology, he is renowned for his expertise in complex pelvic oncologic surgery and his commitment to advancing surgical quality and patient-centered care. A graduate of the University of Madrid, Dr. Chiva completed his gynecologic oncology fellowship at Rush-Presbyterian–St. Luke’s Medical Center in Chicago. He later directed the Gynecologic Oncology Department at MD Anderson Cancer Center Madrid and established educational collaborations with MD Anderson Houston. Dr. Chiva has authored over 100 peer-reviewed publications, delivered more than 300 invited lectures, and spearheaded key educational initiatives such as the international “Meet the Surgeon” program. He has held major leadership roles within ESGO, including serving as council member, chair of the Quality Assurance and Certification Committee, and Editor-in-Chief of the ESGO e-Academy platform. He was presented for Honorary Fellowship in the American College of Surgeons in 2021.  

In this IJGC podcast, Dr. Pedro Ramirez discusses Updates in Radiotherapy in Gynecologic Cancers with Junzo Chino.   Dr. Chino is an Associate Professor of Radiation Oncology and Director of Brachytherapy at the Duke Cancer Center. He has authored over 100 publications in the peer reviewed literature, and his research interests are concentrated in radiation therapy for gynecologic cancer, as well as health services and disparities. He was lead author of the ASTRO guidelines task force for cervical cancer, and served as the GYN section editor at the International Journal of Radiation Oncology Biology and Physics and Associate Editor of the International Journal of Gynecological Cancer. His recent article published in Cancer focuses on Recent advances in gynecologic radiation oncology. 

In this episode of the IJGC conversations 2025 November Editor's Choice, Editorial Fellow Paula Mateo-Kubach and Matteo Loverro discusses the contents of the 2025 November issue of IJGC. 

In this IJGC podcast, Dr. Pedro Ramirez discusses Results of the MoST-CIRCUIT Trial with Oliver Klein.   A/Prof Klein is a clinician-scientist at the Austin Hospital and the ONJCRI with a 20-year experience in the field of cancer immunotherapy and a particular interest in the treatment of rare gynaecological malignancies. Dr Klein pioneered clinical trials using checkpoint blockade in patients with advanced rare cancers including gynaecological malignancies. These trials demonstrated unprecedented clinical outcomes in this patient population of major unmet medical need. Next to his clinical research, Dr Klein participates and leads translational research investigating biological correlates of response to immunotherapy.

In this IJGC podcast, Dr. Pedro Ramirez discusses Addition of Metronidazole to Prevent SSI with Megan Gorman and Marina Frimer.   Dr. Marina Frimer is a gynecologic oncologist and physician-scientist whose work bridges clinical innovation and translational research in gynecologic malignancies. As Associate Professor at the Zucker School of Medicine at Hofstra/Northwell and Associate Chief for Research and Academic Development at Northwell Health, she plays a key role in advancing academic and clinical research programs in women’s cancer. Dr. Frimer’s research focuses on improving surgical and therapeutic outcomes in gynecologic oncology, with a particular emphasis on uterine and endometrial cancers. Her recent publications include a phase II clinical trial investigating niraparib maintenance therapy in uterine serous carcinoma (BMJ Open, 2025), studies on perioperative antibiotic optimization for hysterectomy in gynecologic malignancies (Int J Gynecol Cancer, 2025), and patient-derived organoid models of endometrial cancer (Bio Protoc, 2024).   Dr. Frimer has contributed to influential studies on DNA repair mechanisms, endometrial microbiome, and racial disparities in endometrial cancer. Her work has been published in leading journals such as Gynecologic Oncology, JCO Precision Oncology, and International Journal of Gynecological Cancer, and she has collaborated extensively on multi-institutional and translational research initiatives. Dr. Frimer is recognized for her leadership in mentoring early-career investigators and promoting clinical trial development within Northwell’s gynecologic oncology research program.   Dr. Megan Gorman is a gynecologic oncologist and Assistant Professor at Thomas Jefferson University Hospital in Philadelphia, PA.  Dr. Gorman completed her medical education at the Warren Alpert Medical School of Brown University, her training in obstetrics and gynecology at Stony Brook University Hospital, her fellowship in gynecologic oncology at Zucker School of Medicine at Hofstra/Northwell Long Island Jewish Medical Center. Her recent clinical research in gynecologic malignancies focuses on racial disparities in cancer care, improved surgical outcomes, funding disparities in research,  the role of next generation sequencing, novel therapies, end of life care, and hormone replacement in survivorship. She has also collaborated on translational research initiatives including the development of a patient-derived organoid model of endometrial cancers. Dr. Gorman is passionate about resident education, promoting health literacy, and the treatment of HPV-associated malignancies, and recently completed her second medical mission in Salima, Malawi.

In this IJGC podcast, Dr. Pedro Ramirez discusses Checkpoint Inhibitor Rechallenge in Endometrial Cancer with Brian Slomovitz. Dr. Slomovitz is a Gynecologic Oncologist at Mount Sinai Medical Center in Miami Beach, Florida, and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies.    

In this IJGC podcast, Dr. Pedro Ramirez discusses PEACOCC Trial: Pembrolizumab in Clear Cell Cancer with Rebecca Kristeleit.   Rebecca Kristeleit is a Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust and an Adjunct Associate Professor in the Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences at KCL, London. She is Research Lead for gynaecological cancer, R&D Lead for Oncology and Clinical Lead for Oncology and Haematology Clinical Trials at Guy’s and St Thomas’ NHS Foundation Trust. She works as a Principle Investigator within the KCL Cancer Early Phase Trials Unit, Theme Lead within King’s Health Partners ECMC and is Academic Lead for the King’s Health Partners Gynaecological Cancer Biobank.  Rebecca has extensive experience in experimental therapeutics and associated translational research, particularly molecular selection for therapeutics, as well as Phase II and III clinical trials. She works closely with several academic collaborators at KCL, nationally and internationally. She is currently leading two trial programmes of drugs discovered at KCL, a novel immunotherapy and a solid tumour CAR-T. She mentors and supervises KCL undergraduate and postgraduate students. Rebecca’s primary motivation is to improve treatment options available for patients with gynaecological cancer and she has been instrumental in the development and delivery of new licensed drugs in gynaecological cancer, for example rucaparib, dostarlimab, through clinical trial research leadership. She led the UK academic PEACOCC trial investigating pembrolizumab in clear cell gynaecological cancer and is global Co-Investigator for DOVE, a follow-on international randomised Phase II trial in the same rare indication. She leads many trials nationally and internationally, several in partnership with GTG-UK. Rebecca has published extensively, speaks regularly at International Conferences and has held several national and international research leadership positions including Chair BGCS Scientific Committee, BGCS guidelines committee, BGCS medical oncology representative, Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, CRUK New Agents Committee, ESMO Faculty, Chair ASCO Gynaecological Cancer Scientific Committee, ASCO educational committee.

In this IJGC podcast, Dr. Pedro Ramirez discusses ADCs and Oral Mucositis: Strategies for Gynecologic Oncologists with Michelle D. Lightfoot.   Michelle D. Lightfoot, MD, joined NYU Langone in August 2021 after completing fellowship training in gynecologic oncology at The Ohio State University. She received her medical degree from Harvard Medical School and a master’s in public health from Columbia University’s Mailman School of Public Health, before completing residency training at Beth Israel Deaconess Medical Center/Harvard Medical School. At NYU Langone’s Perlmutter Cancer Center and Bellevue Hospital, Dr. Lightfoot provides clinical care and is committed to training future generations of physicians and gynecologic oncologists. As a physician–researcher, she is dedicated to improving care for women with gynecologic malignancies through research, quality improvement initiatives, and public health measures. She also serves on the Society of Gynecologic Oncology’s policy, quality, and outcomes subcommittee. In collaboration with researchers at NYU Langone Health’s Institute for Excellence in Health Equity, Dr. Lightfoot’s research focuses on identifying and eliminating disparities in cancer care delivery and outcomes among women with gynecologic cancers

In this episode of the IJGC conversations 2025 October Editor's Choice, Editorial Fellow Tommaso Meschini and Carlotta Sabini discusses the contents of the 2025 October issue of IJGC. 

In this IJGC podcast, Dr. Pedro Ramirez discusses ROSELLA Trial: Relacorilant in Platinum-resistant Ovarian Cancer with Alexander B. Olawaiye. Dr. Olawaiye a Professor and  Vice Chair for DI at the Department of Obstetrics, Gynecology and Reproductive Sciences. He is director of gynecologic cancer research at Magee-Women’s Hospital of the University of Pittsburgh Medical Center, and has overseen multiple clinical research projects. He is also the Gynecologic Oncology Group Foundation principal investigator for the University of Pittsburgh Cancer Institute and in this role has collaborated with multiple clinical scientists across the country to conduct phases I, II and III studies. As well as a co-principal investigator on the University of Pittsburgh ovarian cancer SPORE program. Dr. Olawaiye also studies chemotherapeutic agents and their complications, along with mentoring many younger clinicians at the beginning of their academic careers. His recent work published in LANCET, the phase 3 ROSELLA trial, tested the combination of Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer. 

In this IJGC podcast, Dr. Pedro Ramirez discusses Carcinosarcoma with no myoinvasion with Giuseppe Cucinella and Mario M. Leitao, Jr. Giuseppe Cucinella, MD, is a gynecologist working at Istituto Nazionale Tumori IRCSS Fondazione G.Pascale in Naples, Italy (Department of Gynecologic Oncology). During his residency, he worked as a research fellow at Mayo Clinic in Rochester, Minnesota, where he focused on the study of endometrial cancer. He is currently in the second year of the PhD program in "Experimental Oncology and Surgery - Gynecologic Oncology" at the University of Palermo, Palermo (Italy). Dr. Cucinella's clinical research focuses on the diagnosis and treatment of endometrial cancer and minimally invasive surgery in gynecologic oncology.   Dr. Mario M. Leitao, Jr., MD, FACOG, FACS, is currently an Attending Surgeon in the Department of Surgery at Memorial Sloan Kettering Cancer Center and a Professor in the Department of Obstetrics and Gynecology at Weill Cornell Medical College. He currently serves as Program Director for the Gynecologic Oncology Fellowship. Dr. Leitao is also the Director for the Minimal Access and Robotic Surgery Program in the Department of Surgery for MSKCC. Dr. Leitao is the recipient of the 2025 IGCS Excellence in Teaching Award.